osteoclast maturation
Definition
Target type: biologicalprocess
A developmental process, independent of morphogenetic (shape) change, that is required for an osteoclast cell to attain its fully functional state. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue, and which typically differentiates from monocytes. [CL:0000092, GOC:pg]
Osteoclast maturation is a complex process involving the differentiation of hematopoietic stem cells into mature osteoclasts, specialized bone-resorbing cells. This process is tightly regulated by a network of signaling pathways, cytokines, and transcription factors.
**1. Commitment and Progenitor Formation:**
- Osteoclast precursors originate from hematopoietic stem cells in the bone marrow.
- These stem cells commit to the osteoclast lineage under the influence of macrophage colony-stimulating factor (M-CSF).
- M-CSF binds to its receptor, c-Fms, on the precursor cells, triggering their survival, proliferation, and differentiation towards the monocyte/macrophage lineage.
**2. Fusion and Multinucleation:**
- Once committed, osteoclast precursors migrate to bone surfaces and encounter RANKL (receptor activator of nuclear factor kappa-B ligand), a key cytokine for osteoclast differentiation.
- RANKL binds to its receptor, RANK, on the precursor cells, activating downstream signaling pathways.
- This activation leads to the expression of genes involved in cell fusion, resulting in the formation of multinucleated osteoclasts.
**3. Differentiation and Maturation:**
- Mature osteoclasts are characterized by a highly polarized structure with ruffled borders facing the bone surface.
- These ruffled borders are specialized membrane domains enriched in proton pumps and enzymes, facilitating bone resorption.
- During maturation, osteoclasts acquire the ability to express and activate key enzymes, including tartrate-resistant acid phosphatase (TRAP), cathepsin K, and matrix metalloproteinases (MMPs).
- These enzymes are essential for degrading the organic and inorganic components of bone.
**4. Bone Resorption:**
- Mature osteoclasts attach to the bone surface and form a sealed compartment called the resorption lacuna.
- They pump protons into this compartment, lowering the pH and dissolving the mineralized bone matrix.
- Osteoclasts also secrete enzymes that degrade the organic components of bone, including collagen and other matrix proteins.
- The degraded bone components are then released into the extracellular space.
**5. Regulation and Control:**
- Osteoclast differentiation and activity are tightly regulated by a complex interplay of stimulatory and inhibitory factors.
- RANKL, produced by osteoblasts and stromal cells, is the primary stimulator of osteoclast differentiation.
- Osteoprotegerin (OPG), another factor secreted by osteoblasts, acts as a decoy receptor for RANKL, blocking its interaction with RANK and inhibiting osteoclast formation.
- Other factors, such as cytokines (e.g., TNF-alpha, IL-1), hormones (e.g., parathyroid hormone), and drugs (e.g., bisphosphonates), can also influence osteoclast activity.
**6. Apoptosis and Clearance:**
- After completing their resorptive function, osteoclasts undergo apoptosis (programmed cell death).
- This process is essential for maintaining bone homeostasis and preventing excessive bone resorption.
- The apoptotic osteoclasts are then phagocytosed by macrophages, clearing the bone surface for new bone formation.'
"
Proteins (1)
Protein | Definition | Taxonomy |
---|---|---|
P2X purinoceptor 5 | A P2X purinoceptor 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q93086] | Homo sapiens (human) |
Compounds (2)
Compound | Definition | Classes | Roles |
---|---|---|---|
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6. pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert | arenesulfonic acid; azobenzenes; methylpyridines; monohydroxypyridine; organic phosphate; pyridinecarbaldehyde | purinergic receptor P2X antagonist |
af 353 | 5-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine: a P2X3 and P2X2/3 receptor antagonist; structure in first source |